Bert B. A. de Vries

Dr. Bert B. A. de Vries


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MGMichael A Gargano
Michael A Gargano
NMNicolas Matentzoglu
Nicolas Matentzoglu
BCBen Coleman
Ben Coleman
EAEunice B Addo-Lartey
Eunice B Addo-Lartey
AAAnna V Anagnostopoulos
Anna V Anagnostopoulos
PRPeter N. Robinson
Peter N. Robinson
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.

1 June 2017 in The American Journal of Human Genetics
Verified
Journal Article
Open access
MGMichele Gabriele
Michele Gabriele
ASAnneke T. Vulto-Van Silfhout
Anneke T. Vulto-Van Silfhout
PGPierre-Luc Germain
Pierre-Luc Germain
AVAlessandro Vitriolo
Alessandro Vitriolo
RKRaman Kumar
Raman Kumar
BVBert B. A. de Vries
Bert B. A. de Vries
Yin and yang 1 (YY1) is a well-known zinc-finger transcription factor with crucial roles in normal development and malignancy. YY1 acts both as a repressor and as an activator of gene expression. We have identified 23 individuals with de novo mutations or deletions of YY1 and phenotypic features that define a syndrome of cognitive impairment, behavioral alterations, intrauterine growth restriction, feeding problems, and various congenital malformations. Our combined clinical and molecular data define "YY1 syndrome" as a haploinsufficiency syndrome. Through immunoprecipitation of YY1-bound chromatin from affected individuals' cells with antibodies recognizing both ends of the protein, we show that YY1 deletions and missense mutations lead to a global loss of YY1 binding with a preferential retention at high-occupancy sites. Finally, we uncover a widespread loss of H3K27 acetylation in particular on the YY1-bound enhancers, underscoring a crucial role for YY1 in enhancer regulation. Collectively, these results define a clinical syndrome caused by haploinsufficiency of YY1 through dysregulation of key transcriptional regulators.

9 September 2015 in European Journal of Human Genetics
Verified
Journal Article
Closed access
DBDaniëlle Gm Bosch
Daniëlle Gm Bosch
FBF Nienke Boonstra
F Nienke Boonstra
NLNicole de Leeuw
Nicole de Leeuw
RPRolph Pfundt
Rolph Pfundt
WNWilly M Nillesen
Willy M Nillesen
BVBert B. A. de Vries
Bert B. A. de Vries

1 February 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
DBDaniëlle G.M. Bosch
Daniëlle G.M. Bosch
FBF. Nienke Boonstra
F. Nienke Boonstra
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
MXMafei Xu
Mafei Xu
JLJoep de Ligt
Joep de Ligt
CSChristian Schaaf
Christian Schaaf

31 December 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
WBWei Ba
Wei Ba
YYYan Yan
Yan Yan
MRMargot R.F. Reijnders
Margot R.F. Reijnders
JSJanneke H.M. Schuurs-Hoeijmakers
Janneke H.M. Schuurs-Hoeijmakers
IFIlse Feenstra
Ilse Feenstra
BVBert B. A. de Vries
Bert B. A. de Vries
Recently, we marked TRIO for the first time as a candidate gene for intellectual disability (ID). Across diverse vertebrate species, TRIO is a well-conserved Rho GTPase regulator that is highly expressed in the developing brain. However, little is known about the specific events regulated by TRIO during brain development and its clinical impact in humans when mutated. Routine clinical diagnostic testing identified an intragenic de novo deletion of TRIO in a boy with ID. Targeted sequencing of this gene in over 2300 individuals with ID, identified three additional truncating mutations. All index cases had mild to borderline ID combined with behavioral problems consisting of autistic, hyperactive and/or aggressive behavior. Studies in dissociated rat hippocampal neurons demonstrated the enhancement of dendritic formation by suppressing endogenous TRIO, and similarly decreasing endogenous TRIO in organotypic hippocampal brain slices significantly increased synaptic strength by increasing functional synapses. Together, our findings provide new mechanistic insight into how genetic deficits in TRIO can lead to early neuronal network formation by directly affecting both neurite outgrowth and synapse development.

16 September 2022 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
BSBart P. G. H. van der Sanden
Bart P. G. H. van der Sanden
GSGaby Schobers
Gaby Schobers
JGJordi Corominas Galbany
Jordi Corominas Galbany
DKDavid A. Koolen
David A. Koolen
MSMargje Sinnema
Margje Sinnema
LVLisenka E. L. M. Vissers
Lisenka E. L. M. Vissers
Genome sequencing (GS) can identify novel diagnoses for patients who remain undiagnosed after routine diagnostic procedures. We tested whether GS is a better first-tier genetic diagnostic test than current standard of care (SOC) by assessing the technical and clinical validity of GS for patients with neurodevelopmental disorders (NDD). We performed both GS and exome sequencing in 150 consecutive NDD patient-parent trios. The primary outcome was diagnostic yield, calculated from disease-causing variants affecting exonic sequence of known NDD genes. GS (30%,n = 45) and SOC (28.7%,n = 43) had similar diagnostic yield. All 43 conclusive diagnoses obtained with SOC testing were also identified by GS. SOC, however, required integration of multiple test results to obtain these diagnoses. GS yielded two more conclusive diagnoses, and four more possible diagnoses than ES-based SOC (35 vs. 31). Interestingly, these six variants detected only by GS were copy number variants (CNVs). Our data demonstrate the technical and clinical validity of GS to serve as routine first-tier genetic test for patients with NDD. Although the additional diagnostic yield from GS is limited, GS comprehensively identified all variants in a single experiment, suggesting that GS constitutes a more efficient genetic diagnostic workflow.